Cognition Therapeutics to Report Q4 and Year End 2025 Financial Results on March 26, 2026.

lunes, 23 de marzo de 2026, 7:32 am ET1 min de lectura
CGTX--

Cognition Therapeutics plans to release Q4 and full-year 2025 financial results on March 26, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Cognition is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative disorders, with its lead candidate, zervimesine (CT1812), showing promise in Phase 2 clinical trials for dementia with Lewy bodies and Alzheimer's disease.

Cognition Therapeutics to Report Q4 and Year End 2025 Financial Results on March 26, 2026.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios